ximelagatran   Click here for help

GtoPdb Ligand ID: 6381

Synonyms: H 376-95 | H 376/95
Approved drug
ximelagatran is an approved drug
Compound class: Synthetic organic
Comment: Ximelagatran is a prodrug of the active prothrombin inhibitor melagatran. Applications for approval of ximelagatran were withdrawn in 2006.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 146.35
Molecular weight 473.26
XLogP 2.39
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCOC(=O)CNC(C(=O)N1CCC1C(=O)NCc1ccc(cc1)C(=NO)N)C1CCCCC1
Isomeric SMILES CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(cc1)/C(=N/O)/N)C1CCCCC1
InChI InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
InChI Key ZXIBCJHYVWYIKI-PZJWPPBQSA-N
No information available.
Summary of Clinical Use Click here for help
Ximelagatran is a prodrug, that is metabolised in the liver to generate a direct thrombin inhibitor. It was investigated as an orally administered prophylactic for deep venous thrombosis, prevention of secondary venous thromboembolism and complications of atrial fibrillation, as a replacement for warfarin. Ximelagatran did receive marketing authorisation in several countries (Germany, Portugal, Sweden, Finland, Norway, Iceland, Austria, Denmark, France, Switzerland, Argentina and Brazil), but the drug was later discontinued by AstraZeneca due to the risk of hepatotoxicity. The FDA informed AstraZeneca that they would not approve ximelagatran in 2004.